التفاصيل البيبلوغرافية
| العنوان: |
The effects of rosiglitazone on myocardial triglyceride content in patients with type 2 diabetes: A randomised, placebo-controlled trial |
| المؤلفون: |
McGavock, Jonathan, Szczepaniak, Lidia S, Ayers, Colby R, Abdullah, Shuaib M, See, Raphael, Gore, M Odette, Drazner, Mark H, de Lemos, James A, McGuire, Darren K |
| المصدر: |
Diabetes and Vascular Disease Research ; volume 9, issue 2, page 131-137 ; ISSN 1479-1641 1752-8984 |
| بيانات النشر: |
SAGE Publications |
| سنة النشر: |
2011 |
| مصطلحات موضوعية: |
Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Internal Medicine |
| الوصف: |
This was a nested sub-study of a randomised placebo-controlled trial of the effect of 6 months of treatment with rosiglitazone added to existing therapy on myocardial triglyceride (mTG) content in patients with type 2 diabetes (T2D) and prevalent cardiovascular disease (CVD) or at least one additional risk factor. The primary endpoint, mTG content, was measured with cardiac 1 H-magnetic resonance spectroscopy. Of the 99 randomised participants selected for the imaging sub-study, 49 (48%) had complete and interpretable spectroscopy data (age = 58 years, duration of T2D = 9.5 years; 57% women and 69% non-white). There was no significant change in mTG in either group (−0.1 ± 0.6% and −0.05 ± 0.8% respectively) and the changes in mTG were not associated with changes in left ventricular structure or function. Compared with placebo, treatment with rosiglitazone for 6 months had no discernible effect on mTG or left ventricular function in this population with long-standing diabetes and CVD. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1177/1479164111428628 |
| الإتاحة: |
https://doi.org/10.1177/1479164111428628Test |
| حقوق: |
http://journals.sagepub.com/page/policies/text-and-data-mining-licenseTest |
| رقم الانضمام: |
edsbas.1104422C |
| قاعدة البيانات: |
BASE |
